Endocrine & hormone · target hub
Insulin receptor substrate 2 (IRS2)
IRS2 is a Metabolic / incretin hormones on the endocrine & hormone axis. IRS2 participates in PI3K/Akt/mTOR signaling—see UniProt and primary literature for isoforms and tissue context. It is indexed under "Insulin–glucagon–incretin axis" on our pathway page for antibodies, inhibitors, and assay guidance.
| Type / example | Domain / context (brief) |
|---|---|
| Expression context | Tissue/cell-type–dependent expression |
| Rare variants | Sporadic variants—require functional validation |
| Pathway coupling | Co-occurs with neighboring nodes on the hub |
Naming and prevalence vary by cohort and assay—annotate clinically with COSMIC, ClinVar, OncoKB, and datasheets; research context only.
Examples below reflect common literature and public resources (e.g., CCLE, DepMap)—validate genotypes, expression, and passage in your own stocks before committing assays.
Human tissues and primary cells require ethics/IRB approval; tumors are heterogeneous—record histotype, site, and preservation conditions.
Overexpression vs endogenous IRS2 can differ in dosage, splicing, and compartmentation—in organoids/PDX, record passage, matrix, and drug history.
Adds IRS2 keyword bias atop the 内分泌和激素 antibody pool—if sparse, use presets above or global search.
This content supports research reagents and pathway education—not medical advice. Annotate mutations, drug indications, and protocols with authoritative databases, datasheets, and institutional oversight.
Last reviewed: 2026-05-18
See the endocrine & hormone hub for neighboring targets—cross-check PI3K, MAPK, RTK, and metabolism pages as needed.